Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade.
about
Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapyAldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.Pressure-induced renal injury in angiotensin II versus norepinephrine-induced hypertensive rats.Modulation of angiotensin II-induced inflammatory cytokines by the Epac1-Rap1A-NHE3 pathway: implications in renal tubular pathobiology.Role of renal perfusion pressure versus angiotensin II on renal oxidative stress in angiotensin II-induced hypertensive rats.Clusterin/apolipoprotein J attenuates angiotensin II-induced renal fibrosisShort-term treatment with diminazene aceturate ameliorates the reduction in kidney ACE2 activity in rats with subtotal nephrectomy.Metabolically healthy obesity and risk of incident CKD.Role of AT₁ receptor-mediated salt retention in angiotensin II-dependent hypertension.Lymphocyte responses exacerbate angiotensin II-dependent hypertension.IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis.Role of blood pressure and the renin-angiotensin system in development of diabetic nephropathy (DN) in eNOS-/- db/db mice.Differential pharmacology and benefit/risk of azilsartan compared to other sartansThe Impact of Renin-Angiotensin System Blockade on Renal Outcomes and Mortality in Pre-Dialysis Patients with Advanced Chronic Kidney Disease.Treatment with enalapril and not diltiazem ameliorated progression of chronic kidney disease in rats, and normalized renal AT1 receptor expression as measured with PET imaging.Obesity and diabetic kidney disease.Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertensionAdverse renal consequences of obesity.Blood pressure-renal blood flow relationships in conscious angiotensin II- and phenylephrine-infused ratsImmune and inflammatory role in renal disease.Protective importance of the myogenic response in the renal circulation.Chronic kidney disease: blood-pressure targets in chronic kidney disease.Renal microvascular dysfunction, hypertension and CKD progression.Increased Apoptosis in the Paraventricular Nucleus Mediated by AT1R/Ras/ERK1/2 Signaling Results in Sympathetic Hyperactivity and Renovascular Hypertension in Rats after Kidney Injury.Intrarenal distributions and changes of Angiotensin-converting enzyme and Angiotensin-converting enzyme 2 in feline and canine chronic kidney disease.Uncritical acceptance of combination treatment of angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor in nondiabetic renal disease trial results.Effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney disease.ANG II receptor blockade enhances anti-inflammatory macrophages in anti-glomerular basement membrane glomerulonephritis.Angiotensin II receptor blockade inhibits acute glomerular injuries with the alteration of receptor expression.Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination.The Clinical Usefulness of Measurement of Visceral Fat Area Using Multi-Frequency Bioimpedance: The Association with Cardiac and Renal Function In General Population with Relatively Normal Renal Function.S100 Proteins As an Important Regulator of Macrophage Inflammation.The calcimimetic R-568 prevents podocyte loss in uninephrectomized ApoE-/- mice.Hypertensive Kidney Injury and the Progression of Chronic Kidney Disease.
P2860
Q26751126-3B57B5CB-DC7D-4067-9ABE-3E345E059BDBQ33414957-C36606E0-2939-4957-8668-6C181ACEDECBQ33614801-B13F02F4-6C42-4175-8E39-229F1F42ADABQ33701556-61FCAB20-3238-45E6-9D42-B9506ACDF0A4Q33907355-E13A3113-338F-4527-907E-EC7C7CFC3BADQ34078756-0D77B719-17F4-4915-B6B4-60E7E136E172Q35192530-A7BF939C-5FB0-444B-A942-9664B91ABC5BQ35278585-B8511D2B-834D-4ACD-8A2F-BF309B658B6EQ35543201-6FD0952E-DF7C-4CDB-BC58-AF69C4EF320BQ35576468-7CAC005B-9DED-4072-8617-C46C84721BCAQ35691372-0711C63F-C9EB-4174-99C5-6BB03EF4714CQ35787422-A321DFB9-6A49-4592-AFE9-5DD5E247999CQ35808748-04529EB0-4897-4B8B-A7DD-084B84F9C9ACQ36259972-323002A8-9A75-41D3-A925-D5B7A6B818EEQ36380142-1FA04338-7FA9-45B0-A190-B8E92DF4FC68Q36515043-A7FE8DFF-C936-451A-A31A-C7070A3C9E37Q36844520-B4AA6191-3084-4677-B394-02CE319FEA60Q37072213-2860AEAE-7F37-46E4-AC57-2C8281ED1A5BQ37234782-7979039D-7ADF-42B4-A6F8-17F6546179F8Q37243199-57095644-08D5-41E1-9E13-8A94BEF07F2EQ37421982-AB29CD6A-F4F8-4FC0-BE1C-E1DAA6D7E24EQ37572221-BA5BED73-10F0-45E6-B40E-AB0FE07653DBQ37618335-DD117E42-A5B0-431E-8321-49DD93A9AF25Q37620005-3302CF09-2DAA-40FE-8C93-63DF535F8A18Q38664048-A208C54D-BA87-45DE-B615-7F11D1753EC2Q41878402-F177FE1A-B689-4180-A859-8A8AB7B386C2Q43112990-565DBD74-28A0-4ED1-A427-82521CCA881CQ43195252-B47C0476-EB7C-456D-B034-D6C6BF8F2F5DQ46165787-552A1FD4-7FA3-463A-A043-9DA92FDABFC2Q46628598-73DB0DED-E506-4446-9D2A-F62971D30C3CQ47158493-7D706B1A-0488-4A1B-A131-68737C4F4FF6Q49497885-FD57B21A-6FAE-4825-A0A3-37B79D38D901Q50970292-AB2B05E4-18A8-4650-8823-C8796D212452Q53764059-D0EF1485-CAE1-4652-ABD2-78612D0AEFAC
P2860
Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Progression of renal disease: ...... n-angiotensin system blockade.
@en
type
label
Progression of renal disease: ...... n-angiotensin system blockade.
@en
prefLabel
Progression of renal disease: ...... n-angiotensin system blockade.
@en
P356
P1476
Progression of renal disease: ...... n-angiotensin system blockade.
@en
P2093
Anil K Bidani
Karen A Griffin
P304
P356
10.2215/CJN.02231205
P577
2006-07-12T00:00:00Z